A decade of progress in lymphoma

Advances and continuing challenges

Christopher R. Flowers, James Olen Armitage

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Our ability to manage patients with non-Hodgkin lymphoma and Hodgkin lymphoma has improved dramatically in the past decade. The survival of patients with the two most frequent lymphomas (ie, diffuse large B-cell lymphoma and follicular lymphoma), have improved significantly with the incorporation of rituximab as a standard treatment regimen. New insights into the biology of lymphomas provided by studying patterns of gene expression have improved our ability to classify these diseases. Identifying the treatments most effective with different patterns of gene expression offers the opportunity to further improve treatment outcomes. We now cure most patients with Hodgkin lymphoma, but the past decade has seen advances in our ability to identify patients who are most likely to be cured with less toxic treatment approaches. Unfortunately, our ability to improve the treatment of patients with peripheral T-cell lymphoma has not kept pace with the management of those suffering from B-cell lymphomas. However, better classification systems, improved understanding of the biology of these disorders, and clinical trials aimed specifically at identifying optimal regimens for patients with aggressive peripheral T-cell lymphomas offer hope to improve treatment results over the next decade.

Original languageEnglish (US)
Pages (from-to)414-423
Number of pages10
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number6
DOIs
StatePublished - Jan 1 2010

Fingerprint

Lymphoma
Peripheral T-Cell Lymphoma
B-Cell Lymphoma
Hodgkin Disease
Therapeutics
Gene Expression
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Poisons
Non-Hodgkin's Lymphoma
Clinical Trials
Survival

Keywords

  • B cell
  • Disease classification
  • Rituximab
  • T cell

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A decade of progress in lymphoma : Advances and continuing challenges. / Flowers, Christopher R.; Armitage, James Olen.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 6, 01.01.2010, p. 414-423.

Research output: Contribution to journalReview article

@article{7181b85a7ba745db82443fc348558a36,
title = "A decade of progress in lymphoma: Advances and continuing challenges",
abstract = "Our ability to manage patients with non-Hodgkin lymphoma and Hodgkin lymphoma has improved dramatically in the past decade. The survival of patients with the two most frequent lymphomas (ie, diffuse large B-cell lymphoma and follicular lymphoma), have improved significantly with the incorporation of rituximab as a standard treatment regimen. New insights into the biology of lymphomas provided by studying patterns of gene expression have improved our ability to classify these diseases. Identifying the treatments most effective with different patterns of gene expression offers the opportunity to further improve treatment outcomes. We now cure most patients with Hodgkin lymphoma, but the past decade has seen advances in our ability to identify patients who are most likely to be cured with less toxic treatment approaches. Unfortunately, our ability to improve the treatment of patients with peripheral T-cell lymphoma has not kept pace with the management of those suffering from B-cell lymphomas. However, better classification systems, improved understanding of the biology of these disorders, and clinical trials aimed specifically at identifying optimal regimens for patients with aggressive peripheral T-cell lymphomas offer hope to improve treatment results over the next decade.",
keywords = "B cell, Disease classification, Rituximab, T cell",
author = "Flowers, {Christopher R.} and Armitage, {James Olen}",
year = "2010",
month = "1",
day = "1",
doi = "10.3816/CLML.2010.n.086",
language = "English (US)",
volume = "10",
pages = "414--423",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - A decade of progress in lymphoma

T2 - Advances and continuing challenges

AU - Flowers, Christopher R.

AU - Armitage, James Olen

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Our ability to manage patients with non-Hodgkin lymphoma and Hodgkin lymphoma has improved dramatically in the past decade. The survival of patients with the two most frequent lymphomas (ie, diffuse large B-cell lymphoma and follicular lymphoma), have improved significantly with the incorporation of rituximab as a standard treatment regimen. New insights into the biology of lymphomas provided by studying patterns of gene expression have improved our ability to classify these diseases. Identifying the treatments most effective with different patterns of gene expression offers the opportunity to further improve treatment outcomes. We now cure most patients with Hodgkin lymphoma, but the past decade has seen advances in our ability to identify patients who are most likely to be cured with less toxic treatment approaches. Unfortunately, our ability to improve the treatment of patients with peripheral T-cell lymphoma has not kept pace with the management of those suffering from B-cell lymphomas. However, better classification systems, improved understanding of the biology of these disorders, and clinical trials aimed specifically at identifying optimal regimens for patients with aggressive peripheral T-cell lymphomas offer hope to improve treatment results over the next decade.

AB - Our ability to manage patients with non-Hodgkin lymphoma and Hodgkin lymphoma has improved dramatically in the past decade. The survival of patients with the two most frequent lymphomas (ie, diffuse large B-cell lymphoma and follicular lymphoma), have improved significantly with the incorporation of rituximab as a standard treatment regimen. New insights into the biology of lymphomas provided by studying patterns of gene expression have improved our ability to classify these diseases. Identifying the treatments most effective with different patterns of gene expression offers the opportunity to further improve treatment outcomes. We now cure most patients with Hodgkin lymphoma, but the past decade has seen advances in our ability to identify patients who are most likely to be cured with less toxic treatment approaches. Unfortunately, our ability to improve the treatment of patients with peripheral T-cell lymphoma has not kept pace with the management of those suffering from B-cell lymphomas. However, better classification systems, improved understanding of the biology of these disorders, and clinical trials aimed specifically at identifying optimal regimens for patients with aggressive peripheral T-cell lymphomas offer hope to improve treatment results over the next decade.

KW - B cell

KW - Disease classification

KW - Rituximab

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=79952982718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952982718&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.086

DO - 10.3816/CLML.2010.n.086

M3 - Review article

VL - 10

SP - 414

EP - 423

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -